2025-09-14 - Analysis Report
Okay, here's an analysis of Natera Inc. (NTRA) based on the information you provided.

## NTRA Stock Analysis

**Ticker:** NTRA
**Company:** Natera Inc.
**Description:** Natera Inc. is a diagnostics company specializing in cell-free DNA testing.

### 1. Performance vs. S&P 500 (VOO)

*   **NTRA Cumulative Return:** 155.11%
*   **VOO Cumulative Return:** 89.18%
*   **Absolute Divergence:** 665.6 (NTRA significantly outperformed VOO)
*   **Relative Divergence:** 96.1 (NTRA's outperformance is in the 96.1th percentile of its historical divergence range)

**Analysis:** NTRA has significantly outperformed the S&P 500. The relative divergence indicates this outperformance is historically high.

**Alpha, Beta Analysis:**

| Year       | CAGR     | MDD   | Alpha    | Beta | Cap (B) |
|------------|----------|-------|----------|------|---------|
| 2015-2017  | -9.0%    | 4.5%  | -12.0%   | -0.5 | 1.2     |
| 2016-2018  | 18.0%    | 80.0% | 23.0%    | 0.0  | 1.9     |
| 2017-2019  | 150.0%   | 80.0% | 128.0%   | 0.0  | 4.6     |
| 2018-2020  | 519.0%   | 80.0% | 492.0%   | 0.0  | 13.7    |
| 2019-2021  | 348.0%   | 62.9% | 299.0%   | 0.0  | 12.8    |
| 2020-2022  | -116.0%  | 62.9% | -122.0%  | 0.0  | 5.5     |
| 2021-2023  | -470.0%  | 69.9% | -490.0%  | 0.9  | 8.6     |
| 2022-2024  | -72.0%   | 70.6% | -99.0%   | 0.9  | 21.7    |
| 2023-2025  | 107.0%   | 76.1% | 53.0%    | 0.8  | 23.1    |

*   **CAGR:** Wide fluctuations, showing periods of significant growth and substantial losses.
*   **MDD:** High Maximum Drawdown values indicate significant volatility and risk.
*   **Alpha:** Consistently high positive alpha during growth periods, indicating outperformance relative to the market. Negative alpha during downturns.
*   **Beta:** Beta is mostly near 0, suggesting NTRA is not closely correlated with the market. More recently around 0.9.
*   **Cap:** Market Cap has generally increased over time, reflecting growth.

### 2. Recent Stock Price Action

*   **Current Price:** \$168.51
*   **Previous Close:** \$173.81
*   **Change:** -\$3.05 (-3.05%)
*   **5-Day Moving Average:** \$171.17
*   **20-Day Moving Average:** \$166.35
*   **60-Day Moving Average:** \$157.15

**Analysis:** The stock price decreased by -3.05% from the previous close, suggesting a short-term downward trend. The current price is below the 5-day moving average but above the 20-day and 60-day moving averages, suggesting a potential short-term correction within a longer-term upward trend.

### 3. Technical Indicators and Expected Return

*   **Market Risk Indicator (MRI):** 0.3233 (Low Risk)
*   **RSI:** 53.25 (Neutral)
*   **PPO:** -0.0346 (Negative, indicates slightly bearish momentum)
*   **Hybrid Signal:** Cash_0%_Buy 80% of cash (1 shares - Caution - MRI:0.34)
*   **20-Day Relative Divergence Change:** +4.5 (Short-term increase in relative outperformance)
*   **Expected Return:** 44.6% (Long-term, vs. S&P 500)

**Analysis:**

*   The **MRI** suggests a low-risk environment, which is positive.
*   The **RSI** is neutral, indicating neither overbought nor oversold conditions.
*   The **PPO** is slightly negative, suggesting bearish momentum, but the value is close to zero.
*   The **Hybrid Signal** suggests buying a portion of the stock, but with caution due to the MRI value, indicating some level of risk.
*   The recent increase in relative divergence suggests that NTRA's outperformance versus the S&P 500 has improved recently.
*   The **expected return of 44.6%** is a significant potential outperformance over the S&P 500 over the long term (2+ years).
*   The recent price drop (change: -\$3.05) reflects recent volatility. This could be related to the news items discussed below.

### 4. Recent News & Significant Events

*   **Negative News (StockStory):** Multiple articles highlight reasons why NTRA stock is falling.
*   **Potential Value (Simply Wall St.):** One article suggests NTRA might be trading below estimated value.
*   **Positive Catalysts (StockStory):** One article presents 3 reasons to be a fan of Natera.
*   **ARCHER Trial Impact (Simply Wall St.):** The ARCHER trial's potential impact on future valuation is discussed.
*   **Liquid Biopsy Market (GlobeNewswire):** A report mentions Natera as a key player in the liquid biopsy market.

**Analysis:** Recent news is mixed, with negative headlines about the stock price declining but also positive mentions related to potential value, ARCHER trial impact, and the company's role in the liquid biopsy market. The negative news likely contributed to the recent price drop.

### 4-2. Analyst Opinions

*   **Consensus:** Strong Buy
*   **Mean Rating:** 1.45 (Strong Buy)
*   **Number of Opinions:** 20
*   **Target Price:**
    *   **Average:** \$198.45
    *   **High:** \$268.00
    *   **Low:** \$37.00

**Analysis:** Analyst sentiment is overwhelmingly positive, with a "Strong Buy" consensus and a high average target price significantly above the current price. However, the wide range between the high and low target prices suggests some uncertainty among analysts. Recent rating changes are not provided, so it's difficult to assess if there are any shifts in analyst sentiment.

### 5. Recent Earnings Analysis

| Date       | EPS   | Revenue      |
|------------|-------|--------------|
| 2025-08-08 | -0.74 | \$0.55B      |
| 2025-05-09 | -0.50 | \$0.50B      |
| 2024-11-12 | -0.26 | \$0.44B      |
| 2024-08-09 | -0.30 | \$0.41B      |
| 2025-08-08 | -0.30 | \$0.41B      |

**Analysis:** While revenue has generally increased over the last few quarters, the company is consistently reporting negative EPS, indicating a lack of profitability.

### 6. Financial Information

**Revenue and Profitability:**

| Quarter    | Revenue | Profit Margin |
|------------|---------|---------------|
| 2025-06-30 | \$0.55B | 63.41%        |
| 2025-03-31 | \$0.50B | 63.12%        |
| 2024-12-31 | \$0.48B | 62.94%        |
| 2024-09-30 | \$0.44B | 61.79%        |
| 2024-06-30 | \$0.41B | 58.83%        |

**Capital and Profitability:**

| Quarter    | Equity  | ROE      |
|------------|---------|----------|
| 2025-06-30 | \$1.25B | -8.10%   |
| 2025-03-31 | \$1.24B | -5.40%   |
| 2024-12-31 | \$1.20B | -4.50%   |
| 2024-09-30 | \$0.88B | -3.60%   |
| 2024-06-30 | \$0.84B | -4.48%   |

**Analysis:**

*   **Revenue:** Revenue has been consistently growing, demonstrating increasing sales.
*   **Profit Margin:** High profit margins, consistently above 58%, indicate strong pricing power or efficient operations.
*   **Equity:** Equity has increased significantly, reflecting a strengthening balance sheet.
*   **ROE:** Negative ROE values indicate the company is currently generating losses on its equity investments. This is consistent with the negative EPS.

### 7. Summary

Natera (NTRA) is a growth-oriented diagnostics company with a strong presence in the liquid biopsy market.

**Key Positives:**

*   **Significant Outperformance:** NTRA has significantly outperformed the S&P 500 historically.
*   **Strong Revenue Growth:** Revenue is consistently increasing.
*   **High Profit Margins:** The company boasts high profit margins.
*   **Strong Analyst Sentiment:** Analysts have a "Strong Buy" consensus and a high average target price.
*   **Increasing Equity:** The company's equity is increasing, strengthening its balance sheet.
*   **Positive Long-Term Expected Return:** 44.6% expected return vs. S&P 500

**Key Negatives/Risks:**

*   **Lack of Profitability:** The company is currently not profitable, as indicated by negative EPS and ROE.
*   **High Volatility:** The stock experiences significant volatility.
*   **Mixed News:** Recent news includes negative headlines about the stock price decline.
*   **Beta:** Relatively low beta for much of history, but now showing more sensitivity to market with beta around 0.9

**Overall:**

NTRA appears to be a high-growth, high-risk investment. The company has strong revenue growth and analyst support, but profitability remains a concern. The recent stock price decline and negative news highlights the volatility associated with this stock. Investors should carefully consider their risk tolerance and investment horizon before investing in NTRA. It appears that the market is reacting to the lack of profitability despite the company's high revenue growth and strong position in the liquid biopsy market.
